METABOLIC & WEIGHT RESEARCH / MATRIX
Three Metabolic Peptides, Side by Side
Where retatrutide, MOTS-c, and tesamorelin converge, where they diverge, and how far the evidence behind each one actually reaches.
The short version
This page lines up retatrutide, MOTS-c, and tesamorelin on the dimensions that matter most when reading metabolic research peptides: molecular class, primary study indication, strength and species of evidence, administration route, regulatory standing, and the single biggest caution for each. The headline is this: the three represent very different stages of the translational pipeline. Tesamorelin has an approved indication with five completed RCTs confirming its effect in a specific population. Retatrutide has compelling Phase 2 data but no approval and ongoing Phase 3 trials. MOTS-c has no human efficacy trials at all — only cell and animal work, plus a biomarker association in one clinical cohort. None is a general-purpose treatment. None is presented here with a human dose.
The comparison matrix
| Dimension | Retatrutide | MOTS-c | Tesamorelin |
|---|---|---|---|
| Peptide class | Investigational GIP/GLP-1/glucagon receptor triple agonist (39 aa) | Mitochondrial-derived peptide (MDP); AMPK activator via folate cycle (16 aa) | Synthetic GHRH analogue, DPP-IV-resistant (44 aa) |
| Most-studied in | Obesity, type 2 diabetes, MASLD (liver fat) | Skeletal muscle glucose uptake, exercise physiology, aging | HIV-associated lipodystrophy (visceral fat reduction) |
| Evidence base (model) | Humans (Phase 1b + Phase 2 RCTs); Phase 3 ongoing [4][5] | Mice and rats; one human biomarker cohort study [9][11] | Humans (FDA-approved; 5 completed RCTs, 2026 meta-analysis) [13] |
| Administration studied | Subcutaneous injection, once weekly [6] | Subcutaneous/IP in animals; no validated human route [10] | Subcutaneous injection, once daily [15][16] |
| Regulatory / WADA status | Investigational — not approved; not specifically WADA-prohibited as of mid-2026 [1] | Not approved; WADA-prohibited (metabolic modulator category) | FDA-approved for HIV lipodystrophy (NDA 022505, 2010); WADA S2 prohibited [14] |
| Key caution | Unapproved; gray-market supply unverified; ongoing heart-rate and GI risk [4] | No human efficacy trials; no validated human PK; ancestry-dependent effects [10] | Narrow approved indication; VAT reaccumulation on discontinuation; IGF-1 elevation [14][17] |
Peptide class
The three are structurally and mechanistically distinct. Retatrutide is a 39-amino-acid acylated peptide engineered to agonize three incretin and metabolic hormone receptors on a single molecule — GIP, GLP-1, and glucagon [2]. MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome itself, not synthesized from scratch by chemists but copied from an endogenous mitochondrial signal — its mechanism runs through the folate cycle and AMPK, not hormone receptors [10]. Tesamorelin is a 44-amino-acid structural analogue of the body's own GHRH, modified to resist enzymatic degradation and act on the pituitary's GH-release machinery [16].
Most-studied in
The three have distinct research homes. Retatrutide's entire trial program has been in obesity and type 2 diabetes, with a significant liver-fat substudy in MASLD [3][4][5]. MOTS-c research centers on skeletal muscle glucose metabolism, physical performance in aging, and the mitochondria-to-nucleus signaling axis — framed as exercise physiology and healthspan research rather than weight loss per se [11][12]. Tesamorelin's pivotal work is in HIV-associated lipodystrophy — a metabolically complex condition where antiretroviral therapy redistributes fat to the abdomen [13][15][17].
Evidence base (model)
This is where the three separate most clearly. Tesamorelin has the strongest and most mature human evidence: five completed RCTs, a 2026 meta-analysis, and a labeled indication [13]. Retatrutide has compelling Phase 2 RCT data in humans but no completed Phase 3 and no approval [4][5]. MOTS-c has no completed interventional human trials; the strongest human data are a biomarker association in a hemodialysis cohort of 94 patients [9]. The animal-model evidence for MOTS-c is mechanistically rich, but the translational distance to human efficacy is the greatest of the three [11].
Administration studied
Routes track the compounds' pharmacological properties. Retatrutide's C20 acylation achieves an approximately 6-day half-life, supporting once-weekly subcutaneous injection — the same format as tirzepatide and semaglutide [6]. Tesamorelin's shorter half-life (extended from native GHRH but shorter than acylated incretin agonists) requires once-daily subcutaneous injection [16]. MOTS-c has no validated human pharmacokinetic profile; rodent studies have used subcutaneous and intraperitoneal routes at 0.5-15 mg/kg/day, and these parameters cannot be extrapolated to humans [10].
Regulatory / WADA status
Tesamorelin is the only approved compound: FDA NDA 022505 (2010), for HIV lipodystrophy specifically. Outside that indication it is unapproved for any use, and it is WADA S2 prohibited in sport [14]. Retatrutide is in Phase 3 trials as of mid-2026; no approval exists anywhere, and GLP-1/GIP/glucagon receptor agonists are not specifically listed on the WADA Prohibited List as of the current code — athletes should consult the latest list [1]. MOTS-c is treated as a prohibited peptide under WADA's hormone-and-metabolic-modulator category; use by competitive athletes can result in sanctions.
Key caution
Each compound carries a defining caveat. For retatrutide it is dual: the compound is unapproved, meaning gray-market supply cannot be verified as authentic or sterile, and the dose-dependent GI and heart-rate signals documented in Phase 2 operate without clinical oversight in research-use contexts [4]. For MOTS-c it is the absence of human efficacy trials — the entire basis for metabolic and performance claims is animal and mechanistic work, with no validated human dosing whatsoever [10]. For tesamorelin it is the narrow indication: approval was earned in a specific HIV-positive population, visceral fat reliably reaccumulates upon stopping, and IGF-1 elevation from GH-axis stimulation carries a theoretical oncologic caution, though no excess cancer signal appeared in trials [14][17]. Reading all three together, the principle is consistent: mechanism does not equal clinical evidence, and regulatory approval defines, rather than bounds, a compound's evidence base.